Compile Data Set for Download or QSAR
Report error Found 1796 Enz. Inhib. hit(s) with BLAST sequence identity > 85%
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50437434(CHEMBL2409175)
Affinity DataKd:  0.00500nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50172243(CHEMBL3103192)
Affinity DataKd:  0.00600nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010980(CHEMBL4089961)
Affinity DataKd:  0.0160nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010980(CHEMBL4089961)
Affinity DataKd:  0.0160nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010942(CHEMBL4077554)
Affinity DataKd:  0.0370nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010942(CHEMBL4077554)
Affinity DataKd:  0.0370nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50172246(CHEMBL3103191)
Affinity DataKd:  0.0480nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50040717(CHEMBL4099729)
Affinity DataKd:  0.0933nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50040717(CHEMBL4099729)
Affinity DataKd:  0.0940nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142829(US8940736, 391)
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142817(US8940736, 285)
Affinity DataIC50: 0.140nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142774(US8940736, 6)
Affinity DataIC50: 0.150nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142835(US8940736, 402)
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010975(CHEMBL4075338)
Affinity DataKd:  0.162nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010975(CHEMBL4075338)
Affinity DataKd:  0.170nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142775(US8940736, 7)
Affinity DataIC50: 0.170nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142793(US8940736, 161)
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142806(US8940736, 229)
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142784(US8940736, 117)
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142832(US8940736, 395)
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142834(US8940736, 399)
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142777(US8940736, 49)
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142792(US8940736, 160)
Affinity DataIC50: 0.240nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50214466(N-(3-(8-cyano-4-(cyclopropylamino)pyrazolo[1,5-a][...)
Affinity DataKi:  0.260nMAssay Description:Inhibition of human CK2 alphaMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142831(US8940736, 394)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142816(US8940736, 281)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142794(US8940736, 163)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142820(US8940736, 319)
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142818(US8940736, 313)
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142778(US8940736, 55)
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142779(US8940736, 57)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142795(US8940736, 167)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142790(US8940736, 133)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142802(US8940736, 207)
Affinity DataIC50: 0.310nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50450094(CHEMBL4162173)
Affinity DataKd:  0.340nMAssay Description:Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50214473(N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5...)
Affinity DataKi:  0.350nMAssay Description:Inhibition of human CK2 alphaMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50335638(5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-...)
Affinity DataKi:  0.380nMAssay Description:Inhibition of CK2alpha (unknown origin) using RRRADDSDDDDD as substrate in presence of [gamma33P]-ATP by autoradiographyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50335638(5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-...)
Affinity DataKd:  0.380nMAssay Description:Binding affinity to CK2alpha (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142827(US8940736, 382)
Affinity DataIC50: 0.390nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010943(CHEMBL4075701)
Affinity DataKd:  0.400nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50450092(CHEMBL4169451)
Affinity DataKd:  0.400nMAssay Description:Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142796(US8940736, 173)
Affinity DataIC50: 0.410nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010971(CHEMBL4069112)
Affinity DataKd:  0.417nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010971(CHEMBL4069112)
Affinity DataKd:  0.420nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50028301(CHEMBL4061407)
Affinity DataKd:  0.5nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50335638(5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-...)
Affinity DataIC50: 0.5nMAssay Description:Displacement of 5-TAMRA-labeled ARC-1530 from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142822(US8940736, 328)
Affinity DataIC50: 0.520nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010963(CHEMBL4076226)
Affinity DataKd:  0.550nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010963(CHEMBL4076226)
Affinity DataKd:  0.550nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha Casein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50335638(5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-...)
Affinity DataKd:  0.560nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMedPDB3D3D Structure (crystal)
Displayed 1 to 50 (of 1796 total ) | Next | Last >>
Jump to: